Tags

Type your tag names separated by a space and hit enter

IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation.
J Med Virol 1998; 56(3):224-9JM

Abstract

The differential diagnosis of recurrent hepatitis C following orthotopic liver transplantation (OLT) may be difficult. We evaluated the diagnostic significance of IgM anti-hepatitis C virus (anti-HCV) core antibodies in 27 patients undergoing OLT because of HCV-associated cirrhosis. Serial serum samples collected before and after OLT were tested for the presence of IgM anti-HCV core antibodies. Results were compared with the histological evidence of liver damage, the presence, level, and genotype of serum HCV RNA and the degree of immunosuppression. All patients underwent recurrent HCV infection. Recurrent hepatitis was diagnosed histologically in 21 patients an average of 48 weeks after OLT (range 2-209 weeks): 18 had persistence or (re-)appearance of the IgM anti-HCV core after OLT, one lost the IgM anti-HCV core after OLT, and two never secreted IgM anti-HCV core either before or after OLT. The remaining six patients did not develop recurrent hepatitis after a follow-up of 44-241 weeks from OLT; in these patients, IgM anti-HCV core either disappeared (1 case) or decreased (1 case) after OLT or were persistently negative throughout the study (4 cases). Thus, 18/21 patients with recurrent hepatitis, but only one of six without recurrent hepatitis, secreted IgM anti-HCV core after OLT (P < 0.05). The IgM anti-HCV core levels were not correlated with the level or genotype of serum HCV RNA or the degree of immunosuppression. In conclusion, secretion of IgM anti-HCV core antibodies after OLT seems associated with recurrence of HCV-associated liver disease and may have diagnostic significance.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland. francesco.negro@hcuge.chNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9783689

Citation

Negro, F, et al. "IgM Anti-hepatitis C Virus Core Antibodies as Marker of Recurrent Hepatitis C After Liver Transplantation." Journal of Medical Virology, vol. 56, no. 3, 1998, pp. 224-9.
Negro F, Giostra E, Rubbia-Brandt L, et al. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. J Med Virol. 1998;56(3):224-9.
Negro, F., Giostra, E., Rubbia-Brandt, L., Mentha, G., Colucci, G., Morel, P., ... Hadengue, A. (1998). IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. Journal of Medical Virology, 56(3), pp. 224-9.
Negro F, et al. IgM Anti-hepatitis C Virus Core Antibodies as Marker of Recurrent Hepatitis C After Liver Transplantation. J Med Virol. 1998;56(3):224-9. PubMed PMID: 9783689.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. AU - Negro,F, AU - Giostra,E, AU - Rubbia-Brandt,L, AU - Mentha,G, AU - Colucci,G, AU - Morel,P, AU - Quadri,R, AU - Perrin,L, AU - Hadengue,A, PY - 1998/10/23/pubmed PY - 2000/6/20/medline PY - 1998/10/23/entrez SP - 224 EP - 9 JF - Journal of medical virology JO - J. Med. Virol. VL - 56 IS - 3 N2 - The differential diagnosis of recurrent hepatitis C following orthotopic liver transplantation (OLT) may be difficult. We evaluated the diagnostic significance of IgM anti-hepatitis C virus (anti-HCV) core antibodies in 27 patients undergoing OLT because of HCV-associated cirrhosis. Serial serum samples collected before and after OLT were tested for the presence of IgM anti-HCV core antibodies. Results were compared with the histological evidence of liver damage, the presence, level, and genotype of serum HCV RNA and the degree of immunosuppression. All patients underwent recurrent HCV infection. Recurrent hepatitis was diagnosed histologically in 21 patients an average of 48 weeks after OLT (range 2-209 weeks): 18 had persistence or (re-)appearance of the IgM anti-HCV core after OLT, one lost the IgM anti-HCV core after OLT, and two never secreted IgM anti-HCV core either before or after OLT. The remaining six patients did not develop recurrent hepatitis after a follow-up of 44-241 weeks from OLT; in these patients, IgM anti-HCV core either disappeared (1 case) or decreased (1 case) after OLT or were persistently negative throughout the study (4 cases). Thus, 18/21 patients with recurrent hepatitis, but only one of six without recurrent hepatitis, secreted IgM anti-HCV core after OLT (P < 0.05). The IgM anti-HCV core levels were not correlated with the level or genotype of serum HCV RNA or the degree of immunosuppression. In conclusion, secretion of IgM anti-HCV core antibodies after OLT seems associated with recurrence of HCV-associated liver disease and may have diagnostic significance. SN - 0146-6615 UR - https://www.unboundmedicine.com/medline/citation/9783689/IgM_anti_hepatitis_C_virus_core_antibodies_as_marker_of_recurrent_hepatitis_C_after_liver_transplantation_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0146-6615&amp;date=1998&amp;volume=56&amp;issue=3&amp;spage=224 DB - PRIME DP - Unbound Medicine ER -